Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 6/20 | 0.64 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.64 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.64 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.64 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.64 |
| ▸ | PRLHR | P49683 | 8/20 | 0.57 |
| ▸ | RXFP4 | Q8TDU9 | 4/20 | 0.55 |
| ▸ | RXFP3 | Q9NSD7 | 4/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388675 | 0.99 | SSTR2 (0.63) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL29365137 | 0.99 | SSTR2 (0.63) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL29483309 | 0.95 | SSTR2 (0.60) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL29598819 | 0.94 | SSTR2 (0.59) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL29881963 | 0.94 | SSTR2 (0.59) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL29474805 | 0.92 | SSTR2 (0.60) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL29405695 | 0.87 | SSTR2 (0.49) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL29379828 | 0.80 | TEAD4 (0.55) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| Somatostatin Receptor Ligand SCHEMBL8814211 | 0.80 | PRLHR (0.67) | PRLHRNPFFR2NPY2R | |
| SCHEMBL31171035 | 0.77 | CXCR4 (0.70) | GLP1RGCGRNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | SSTR2 273/4885SSTR1 185/4885SSTR4 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.